CYTO 2024 -- Chronic lymphocytic leukemia (CLL) is the one of the most frequent types of leukemia in western countries and mainly occurs in elderly patients. This type of cancer has an overall survival of 5 years that ranges from 20% among very high-risk patients to more than 90% in those with less-aggressive genetic risk features.

CYTO 2024 -- Adoptive cell therapies (ACT) have emerged as a promising frontier in cancer and autoimmune disorders, harnessing the power of the immune system to combat diseases. However, the full potential of ACT remains elusive, often hindered by challenges such as variable patient responses and limited persistence of infused cells.

WRIB 2024 -- Here we discuss a high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to simultaneously quantify 15 human bile acids (BAs) in patient plasma and the specific validation tests performed to provide analytical data support for clinical studies.

SETAC Europe 2024 -- In the course of conducting OECD 307 and OECD 308 studies, the amount of test substance and its metabolites extracted from the soil or sediment can decline over time, leading to an increase in the amount of residues remaining unextracted. This can only be quantified where radiolabeled test item has been applied.

SETAC Europe 2024 -- Imagine one individual in a crowd of 100,000 people - they would be difficult to locate. But give this individual a large flag to wave and there they are - easy to see. In addition, as they move through the crowd, you can track and follow where they go and the path they have taken.

ARVO 2024 -- The mouse is an important species for the development of gene therapies because transgenic disease models are often available. Mouse eyes are susceptible to complications associated with the subretinal injection procedures because of their small size and relatively large lens.

ARVO 2024 -- Proliferative vitreoretinopathy (PVR) occurs in up to 10% of rhegmatogenous retinal detachments (RRDs) and is the leading cause of RRDs surgical failure, manifesting in poor visual outcomes and recurrent surgical interventions.

SETAC Europe 2024 -- Per- and polyfluoroalkyl substances (PFAS) are a class of synthetic organofluorine compounds that have become a concern due to their persistence in the environment following extensive use over the last few decades.

Adeno-associated virus (AAV) remains the viral vector of choice for in vivo gene therapy. However, there continue to be safety concerns regarding AAV therapeutics. The empty:full ratio of AAV vectors has been highlighted as an important critical quality attribute (CQA).

In the past 7 years, the United States Food and Drug Administration (USFDA) has approved five Adeno-associated virus (AAV)-based gene therapy products treating a range of disorders and deadly monogenic diseases.